Shenzhen Chipscreen Biosciences Co., Ltd.

The company was founded in March 2001 by a team of veteran doctors returning from the US and a pioneer in the field of innovative medicines in China. Adhering to the concept of “originality, safety, efficiency, and China”, the company focuses on research and development of original innovative drugs in the five major fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals that pose a serious threat to human life and health, and is committed to providing patients with innovative mechanism drugs that are affordable, clinically needed, and have revolutionary curative effects. Microchip Biotech was the first company to participate in the Science and Technology Innovation Board and the first biomedical company to go public. The company is an original innovative pharmaceutical company that is driven by core technology and has built a globally competitive product line. The main products are sidabendamide, siglitazide, sioronil, CS12192, CS23546, CS32582, and other products under development. Corporate honors: the title of “Emerging Enterprise of the Year” at the 2019 Guangdong-Hong Kong-Macao Greater Bay Area Listed Companies Annual Meeting and Corporate Social Responsibility Summit; the title of “Leading Enterprise” in the 70th anniversary of the founding of New China in the pharmaceutical industry; and the title of “Leading Enterprise” among the top 20 leading biotechnology enterprises in Shenzhen in 2019.